Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates

• US 6,491,965 B1
• Filed: 12/17/1996
• Issued: 12/10/2002
• Est. Priority Date: 11/30/1995
• Status: Expired due to Fees

• Current Assignee: Hamilton Civic Hospitals Research Development Inc.
• Original Assignee: Hamilton Civic Hospitals Research Development Inc.
• Inventors: Berry, Leslie, Andrew, Maureen
• Primary Examiner(s): PAK, MICHAEL D
• Application Number:
  US08/768,035
• Time in Patent Office: 2,184 Days
• Field of Search: 530/300, 530/350, 530/393, 536/21, 260/123.7, 514/2, 514/21, 427/2.24, 427/2.29, 427/2.1
• US Class Current: 427/2.1
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: A61L 33/0029 using an intermediate layer of polymer
• CPC Class Codes: A61L 33/0041 characterised by the choice of an antithrombatic agent other than heparin heparinoïd A61L33/08; polypeptides A61L33/12
• CPC Class Codes: C08L 5/10 Heparin; Derivatives thereof

Abstract

Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.

Claims

1. A material for use in a medical or prosthetic device, said material comprising a polymer covalently attached to a covalent comjugate composition, said covalent conjugate composition comprising glycosaminoglycans linked to a species by covalent linkage, wherein the species comprises at least one primary amino group, and wherein the species is directly covalently linked via said amino group to a terminal aldose residue of the glycosaminoglycans, said covalent linkages comprising an α

-carbonyl amine formed by a substantial amount of subsequent Amadori rearrangement of an imine resulting from reaction between said amino group and said terminal aldose residue of said glycosaminoglycans,

wherein said glycosaminoglycans are heparin (H) and said amino-containing species is antithrombin III (AT).

2. A prosthetic or medical device comprising the material of claim 1.

3. The material of claim 1, wherein the polymer is a synthetic polymer selected from the group consisting of poly 2-hydroxyethyl methacrylate, poly acrylamide, polyether polyurethane urea (PEUU), polyethylene, polypropylene, polytetrafluoroethylene, poly(vinylchloride), polydimethylsiloxane, an ehtylene-acrylic acid copolymer, Dacron, polyester polyurethane, polyurethane, polycarbonate-polyurethane, polyamide (Nylon) and polystyrene.

4. The device of claim 2 selected from the group consisting of endovascular tubing, a central venous line, a cardiac catheter, a cardiopulmonary bypass circuit, a dialysis circuit, and an in vivo prosthesis.

5. The device of claim 4, wherein the device is endovascular tubing.

6. The device of claim 5, wherein the polymer is polyurethane-polycarbonate.

7. The device of claim 4, wherein the polymer is selected from the group consisting of poly 2-hydroxyethyl methacrylate, poly acrylamide, poly ether polyurethane urea (PEUU), polyethylene, polypropylene, polytetrafluoroethylene, poly(vinylchloride), polydimethylsiloxane, an ethylene-acrylic acid copolymer, Dacron, and polyester-polyurethane, polyurethane, polycarbonate-polyurethane, polyamide (Nylon) and polystyrene.

8. The device of claim 7, wherein the polymer is polycarbonate-polyurethane.

13. A material of claim 1, wherein in said conjugate the molar ratio of amino-containing species to glycosaminoglycan is less than one.

17. A material of claim 1 wherein said linkages comprise an α

-carbonyl amine formed by subsequent Amadori rearrangement to an extent of at least 80%.

18. A material of claim 1 wherein said linkages comprise an α

-carbonyl amine formed by essentially complete subsequent Amadori rearrangement.

27. A material of claim 1 pharmaceutically suitable for contacting blood in a human.

32. A material of claim 1 wherein said covalent conjugate composition is enriched in heparin chains having two pentasaccharides.

35. A material of claim 17 wherein said covalent conjugate composition is enriched in heparin chains having two pentasaccharides.

36. A material of claim 1 wherein said covalent conjugate composition comprises more than 10% heparin chains having two pentasaccharides.

40. A material of claim 1 wherein said covalent conjugate composition comprises more than 20% heparin chains having two pentasaccharides.

48. A material of claim 1, wherein said substantial amount is more than 90%.

9. A material for use in a medical or prosthetic device, said material comprising a polymer in contact with a covalent conjugate composition, said covalent conjugate composition comprising glycosaminoglycans linked to a species by covalent linkages, wherein the species comprises at least one primary amino group, wherein the glycosaminoglycans are heparins, the species is antithrombin III, and the covalent conjugate composition comprises antithrombin III-heparin (ATH), said ATH being covalently attached to the polymer, and wherein the species is directly covalently linked via said amino group to a terminal aldose residue of the glycosaminoglycans to a substantial degree by an α

-carbonyl linkage.

10. The material of claim 9, wherein the polymer is a synthetic polymer selected from the group consisting of poly 2-hydroxyethyl methacrylate, poly acrylamide, poly ether polyurethane urea (PEUU), polyethylene, polypropylene, polytetrafluoroethylene, poly(vinylchloride), polydimethylsiloxane, an ethylene-acrylic acid copolymer, Dacron, polyester-polyurethane, polyurethane, polycarbonate-polyurethane, polyamide (Nylon) and polystyrene.

21. material of claim 9 wherein said substantial degree is to an extent of at least 80%.

22. A material of claim 21 wherein said substantial degree is an essentially complete degree.

28. A material of claim 9 pharmaceutically suitable for contacting blood in a human.

33. A material of claim 9 wherein said covalent conjugate composition is enriched in heparin chains having two pentasaccharides.

37. A material of claim 9 wherein said covalent conjugate composition comprises more than 10% heparin chains having two pentasaccharides.

39. material of claim 21 wherein said covalent conjugate composition comprises more than 10% heparin chains having two pentasaccharides.

41. A material of claim 9 wherein said covalent conjugate composition comprises more than 20% heparin chains having two pentasaccharides.

43. A material of claim 21 wherein said covalent conjugate composition comprises more than 20% heparin chains having two pentasaccharides.

49. A material of claim 9, wherein said substantial degree is more than 90%.

11. A material for use in a medical or prosthetic device, said material comprising a polymer covalently attached to a covalent conjugate composition comprising a substantial amount of glycosaminoglycans covalently bonded to an amino-group containing species by, CO—

CH₂—

NH, said CO CH₂—

portion being derived from said glycosaminoglycans and said —

NH—

portion from an amino group of said species,

wherein said glycosaminoglycans are heparin (H) and said amino-containing species is antithrombin III (AT).

14. A material of claim 11, wherein in said conjugate the molar ratio of amino-containing species to glycosaminoglycan is less than one.

23. a material of claim 11 wherein said substantial degree is to an extent of at least 80%.

25. A material of claim 11 wherein said substantial degree is an essentially complete degree.

29. A material of claim 11 pharmaceutically suitable for contacting blood in a human.

34. A material of claim 11 wherein said covalent conjugate composition is enriched in heparin chains having two pentasaccharides.

38. A material of claim 11 wherein said covalent conjugate composition comprises more than 10% heparin chains having two pentasaccharides.

42. A material of claim 11 wherein said covalent conjugate composition comprises more than 20% heparin chains having two pentasaccharides.

46. A material of claim 11, wherein said substantial degree is more than 90%.

51. A material of claim 11, which is stable at 4°

C. for at least 60 days.

52. A material of claim 11, which is stable at 4°

C. for at least 90 days.

53. A material of claim 11, wherein the heparin component stoichiometrically activates antithrombin III in the covalent conjugate.

54. A material of claim 11, wherein said covalent conjugate composition comprises more than 35% heparin chains having two pentasaccharides.

55. A material of claim 11, wherein said covalent conjugate composition comprises more than 50% heparin chains having two pentasaccharides.

56. a material of claim 11, wherein said conjugate is neutralized with protamine or human platelet factor 4.

57. A material of claim 11, wherein exosite 2 of thrombin is not required for said conjugate to bind thrombin.

58. A material of claim 11, wherein said conjugate activates antithrombin III molecules to be active catalytically, said molecules not being conjugated to said conjugate.

12. A material for use in a medical or prosthetic device, said material comprising a polymer covalently attached to a covalent conjugate composition comprising a substantial amount of a complex of the formula:

glycosaminoglycan CO—

CH₂—

NH-protein,

wherein said glycosaminoglycan is heparin (H) and said protein is antithrombin III (AT).

15. A material of claim 12, wherein in said conjugate the molar ratio of protein to glycosaminoglycan is less than one.

24. A material of claim 12 wherein said substantial degree is to an extent of at least 80%.

26. A material of claim 12 wherein said substantial degree is an essentially complete degree.

30. A material of claim 12 pharmaceutically suitable for contacting blood in a human.

47. A material of claim 12, wherein said substantial degree is more than 90%.

16. A material for use in a medical or prosthetic device, said material comprising a polymer covalently attached to a covalent conjugate, said covalent conjugate comprising a glycosaminoglycan linked to a species by a covalent linkage, wherein the species comprises at least one primary amino group, and wherein the species is directly convalently linked via said amino group to a terminal aldose residue of the glycosaminoglycan, said covalent linkage comprising an α

-carbonyl amine formed by (a) substantial subsequent Amadori rearrangement of an imine resulting from reaction between said amino group and said terminal aldose residue of said glycosaminoglycan and (b) isolation of the rearrangement product,

wherein said glycosaminoglycan are heparin (H) and said amino-containing species is antithrombin III (AT).

19. A material of claim 16 wherein said imine has undergone a subsequent Amadori rearrangement to an extent of at least 80%.

20. A material of claim 19 wherein said imine has undergone essentially complete subsequent Amadori rearrangement.

31. A material of claim 16 pharmaceutically suitable for contacting blood in a human.

50. A material of claim 16, wherein said substantial rearrangement is more than 90%.

44. A material for use in a medical or prosthetic device, said material comprising a polymer covalently attached to a covalent conjugate composition comprising glycosyaminoglycans and molecules comprising at least one amino group, wherein said amino group is directly linked to said glycosaminoglycans by covalent linkages, wherein said conjugate composition is made by the process comprising:

(a) incubating said glycosaminoglycans with said molecules at a pH and for a time sufficient for imine formation between said amino group and a terminal aldose residue of said glycosaminoglycans, and at a time and temperature sufficient for said imines to undergo a substantial amount of subsequent Amadori rearrangement to an α

-carbonyl amine forming said covalent linkages;

(b) isolating said conjugate composition,

or a pharmaceutically acceptable salt of said covalent conjugate composition,

wherein said glycosaminoglycans are heparin (II) and said amino-containing species is antithrombin III (AT).

45. A material of claim 44 wherein said incubating is carried out for about two weeks.

59. A material for use in medical or prosthetic device, saod material comprising a polymer covalently attached to a covalent conjugate composition, said covalent conjugate composition comprising glycosaminoglycans linked to a species by covalent linkages, wherein the species comprises at least one primary amino group, and wherein the species is directly covalently linked via amino group to terminal aldose residue of the glycosaminoglycans, said covalent linkages comprising an α

-carbonyl amine formed by a substantial amount of subsquent Arnadori rearragement of an imine resulting from reaction between said amino group and said terminal aldose residue of said glycosaminoglycans.